Want to Participate in a Clinical Research Trial for Alzheimer's Disease ?
Fill out this quick Pre-Screening Questionnaire
Alzheimer's Disease Clinical Research Trial Studies
Alzheimer's Disease Clinical Research Trial Studies
Sponsor:
Otsuka Pharmaceutical Development:
Name:
Aspect Study
Protocol Number:
20-AVP-786-306
Summary: The Aspect study is a placebo-controlled study evaluating the safety and efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer’s Type.
Eligibility Criteria
Key Inclusion Criteria:
- Probable diagnosis of Dementia of the Alzheimer’s type.
- Caregiver participation required.
Key Exclusion Criteria:
- Dementia other than Alzheimer’s Disease.
- Not currently in any assisted living facility.
- No history of seizures, severe eating disorder or any condition that increases risk of seizures.
- No hospitalization in a mental health facility or living alone.
Patient Time Reimbursed?
Yes
Patient Travel Reimbursed?
Yes
Age:
50-90
Clinicaltrials.gov Link:Â https://clinicaltrials.gov/ct2/show/NCT04408755?term=20-AVP-786-306&draw=2&rank=1
Sponsor Website:Â https://www.otsuka-us.com/
Other Clinical Research Trials Available to Participants
Clinical Trial Studies and those who contribute play a role in the development of new treatments for some of our most common and debilitating diseases and conditions.
Patients who participate in Excell’s clinical trial studies have an opportunity to join the vanguard of scientific research and contribute to the progress, knowledge, and future treatment of medical conditions.
We will provide you with comprehensive information and straightforward answers to your questions regarding the risks and benefits of participating.
Financial compensation may be available to those who qualify and complete visits for Clinical Trial Studies at Excell.
Depression Clinical Research Studies
Sponsor:
Alto Neuroscience
Protocol Number:
ALTO-100-201
Summary: The ALTO-100-201 study is evaluating the safety and efficacy of ALTO-100 used either as monotherapy or adjunctively to an antidepressant. The study includes an optional 4-week open-label portion and is 8 or 16 weeks with 12 potential study visits.
Eligibility Criteria
Key Inclusion Criteria:
- Symptoms of depression for at least 6 weeks prior to entering the study.
- Willing to comply with all study assessments and procedures.
- Willing to either not take an antidepressant medication, or continue taking a single SSRI, SNRI, mirtazapine, or bupropion with no dose changes 2 weeks prior to medication or placebo distribution.
Key Exclusion Criteria:
- Diagnosed with bi-polar disorder, schizophrenia, psychotic disorders, or dementia.
- Primary symptoms of post-traumatic stress disorder.
- Clinically significant medical conditions.
- History of substance abuse in the past 3 months.
Patient Time Reimbursed?
Yes
Patient Travel Reimbursed?
Yes
Age:
18-70
Clinicaltrials.gov Link:Â https://clinicaltrials.gov/study/NCT05712187?term=ALTO-100-201&cond=Depression&rank=1&tab=table
Sponsor Website:Â https://www.altoneuroscience.com/
Generalized Anxiety Clinical Research Studies
Sponsor:
Sunovion Pharmaceuticals
Protocol Number:
SEP361-226
Summary: The Periscope study is a placebo-controlled study evaluating the safety and efficacy of SEP361 n adults with Generalized Anixety Disorder.
Â
Eligibility Criteria:
Key Inclusion Criteria:
- Male or female subject between 18 to 65 years of age.
- Symptoms of Generalized Anxiety Disorder over the past 6 months.
- Primary focus of treatment is Generalized Anxiety Disorder.
Key Exclusion Criteria:
- Diagnosis other than Generalized Anxiety Disorder that was the primary focus of treatment within 12 months before Screening.
- Previous inadequate response to more than 3 antidepressant treatments.
- Any clinically significant unstable medical condition or any clinically significant chronic disease, that would limit the subject’s ability to complete and/or participate in the study.
Patient Time Reimbursed?
Yes
Patient Travel Reimbursed?
Yes
Age:
18 to 65
Clinicaltrials.gov Link:
https://clinicaltrials.gov/study/NCT05729373?term=SEP361-226&aggFilters=status:rec&rank=1&tab=table
Sponsor Website:
Schizophrenia Clinical Research Studies
Sponsor:
Neurocrine
Study Name:
Erudite Study
Protocol Number:
NBI-1065844-CIAS2023
Summary: The Erudite study is evaluating the safety, efficacy, and tolerability of Luvadaxistat in subjects with cognitive impairment associated with schizophrenia.
Eligibility Criteria
Key Inclusion Criteria:
- Experiencing cognitive impairment with a previous diagnosis of Schizophrenia.
- Willing to comply with all study assessments and procedures.
- Currently taking an antipsychotic medication for at least 3 weeks prior to study entry at a 2-6mg Risperidone equivalent.
Key Exclusion Criteria:
- Diagnosed with bi-polar disorder or other non-schizophrenic psychotic disorders.
- Current substance/alcohol abuse.
- Clinically significant medical conditions.
Patient Time Reimbursed?
Yes
Patient Travel Reimbursed?
Yes
Age:
18-50
Clinicaltrials.gov Link:Â https://clinicaltrials.gov/ct2/show/NCT05182476?term=NBI-1065844-CIAS2023&draw=2&rank=1
Sponsor Website:Â https://www.neurocrine.com/
OCD Clinical Research Studies
Sponsor:
Biohaven Pharmaceuticals
Study Name:
Biohaven Study
Protocol Number:
BHV4157-302
Summary: The Biohaven study is a placebo-controlled study evaluating the safety and efficacy of Troriluzole n adults taking an SSRI to treat symptoms of obsessive-compulsive disorder.
Eligibility Criteria:
Key Inclusion Criteria:
- Experiencing moderate to severe symptoms of obsessive-compulsive disorder in the past year.
- Currently taking an SSRI medication for 8 weeks prior to study entry. (Zoloft, Prozac, Lexapro, Celexa, ect.)
- Willing to stop exclusionary psychiatric medications prior to study entry.
Key Exclusion Criteria:
- Lifetime history of bi-polar disorder, schizophrenia, borderline personality disorder or autism spectrum disorders.
- Unwilling to discontinue exclusionary medications or comply with study procedures.
- Any clinically significant unstable medical condition or any clinically significant chronic disease.
Patient Time Reimbursed?
Yes
Patient Travel Reimbursed?
Yes
Age:
18 to 65
Clinicaltrials.gov Link:
https://clinicaltrials.gov/ct2/show/NCT04641143?term=BHV4157-302&draw=2&rank=1
Sponsor Website:
Adolescent Migraine Clinical Research Studies
Sponsor:
AbbVie
Name:
Periscope Study
Protocol Number:
3110-305-002
Summary: The Periscope study is a placebo-controlled study evaluating the safety and efficacy of Ubrogepant in acute treatment of migraine with or without aura in children and adolescents.
Eligibility Criteria
Key Inclusion Criteria:
- History of 1 to 14 migraine attacks per month with moderate to severe headaches in each of the 2 months prior to study entry.
- Current or past use of at least 1 oral medication (over-the-counter medication or prescription medication) for the acute treatment of migraine.
Key Exclusion Criteria:
- Any clinically significant hematologic, endocrine, pulmonary, renal, hepatic, gastrointestinal, cardiovascular, or neurologic disease.
- Other confounding pain syndromes, confounding psychiatric conditions, or other significant neurological disorders other than migraine.
Patient Time Reimbursed?
Yes
Patient Travel Reimbursed?
Yes
Age:
12-17
Clinicaltrials.gov Link:Â https://clinicaltrials.gov/ct2/show/study/NCT05125302?term=3110-305-002&draw=2&rank=2
- Quick Form to See if you Qualify
- Full Questionaire
Please install and activate Contact Form 7 plugin.
Pre-screening questionnaire and your privacy
Please be advised that by filling out the study pre-screening questionnaire, you will be asked to provide personal information, including age, gender, and your current medical condition. One of our staff will then reach out to conduct a phone-screen to see if you qualify for one of our current studies at our office location in Oceanside, CA. Your privacy is of the utmost importance to Excell Research. Your privacy will be protected and the information you provide will only be shared with those involved with the clinical research study if it is determined that you may be eligible to participate, unless you permit us to do so or except as required by law. Your information will not be sold to outside companies, nor will it be stored or collected without your direct consent.
Many pharmaceutical companies and Excell Research are conducting these studies under the Food and Drug Administration (FDA) to learn more about new investigational drugs or treatments. Read our privacy policy to learn more about how your information will be kept private.
Please install and activate Contact Form 7 plugin.
Pre-screening questionnaire and your privacy
Please be advised that by filling out the study pre-screening questionnaire, you will be asked to provide personal information, including age, gender, and your current medical condition. One of our staff will then reach out to conduct a phone-screen to see if you qualify for one of our current studies at our office location in Oceanside, CA. Your privacy is of the utmost importance to Excell Research. Your privacy will be protected and the information you provide will only be shared with those involved with the clinical research study if it is determined that you may be eligible to participate, unless you permit us to do so or except as required by law. Your information will not be sold to outside companies, nor will it be stored or collected without your direct consent.
Many pharmaceutical companies and Excell Research are conducting these studies under the Food and Drug Administration (FDA) to learn more about new investigational drugs or treatments. Read our privacy policy to learn more about how your information will be kept private.
Resources for Alzheimer's Disease
Alzheimer's Disease
Alzheimer’s disease is a brain disorder that gets worse over time. It’s characterized by changes in the brain that lead to deposits of certain proteins. Alzheimer’s disease causes the brain to shrink and brain cells to eventually die. Alzheimer’s disease is the most common cause of dementia — a gradual decline in memory, thinking, behavior and social skills. These changes affect a person’s ability to function.
People with Alzheimer’s disease may:
- Repeat statements and questions over and over.
- Forget conversations, appointments or events.
- Misplace items, often putting them in places that don’t make sense.
- Get lost in places they used to know well.
- Eventually forget the names of family members and everyday objects.
- Have trouble finding the right words for objects, expressing thoughts or taking part in conversations.
